Symbols / IBIO $1.97 -4.37% iBio, Inc.
IBIO Chart
About
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and MUC16 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Market Cap | 71.20M | Enterprise Value | 17.80M | Income | -24.74M | Sales | 300.00K | Book/sh | 1.88 | Cash/sh | 1.53 |
| Dividend Yield | — | Payout | 0.00% | Employees | 20 | IPO | — | P/E | — | Forward P/E | -6.79 |
| PEG | — | P/S | 237.34 | P/B | 1.05 | P/C | — | EV/EBITDA | -0.72 | EV/Sales | 59.34 |
| Quick Ratio | 8.93 | Current Ratio | 9.04 | Debt/Eq | 4.33 | LT Debt/Eq | — | EPS (ttm) | -1.00 | EPS next Y | -0.29 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-02-10 | ROA | -36.99% | ROE | -70.22% | ROIC | — |
| Gross Margin | 100.00% | Oper. Margin | -84.91% | Profit Margin | 0.00% | Shs Outstand | 36.14M | Shs Float | 27.01M | Short Float | 12.19% |
| Short Ratio | 3.73 | Short Interest | — | 52W High | 3.82 | 52W Low | 0.56 | Beta | 1.36 | Avg Volume | 1.03M |
| Volume | 882.10K | Target Price | $5.37 | Recom | Strong_buy | Prev Close | $2.06 | Price | $1.97 | Change | -4.37% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-09 | main | Chardan Capital | Buy → Buy | $5 |
| 2026-03-18 | main | Chardan Capital | Buy → Buy | $5 |
| 2026-03-03 | init | Jones Trading | — → Buy | $7 |
| 2026-02-12 | main | Chardan Capital | Buy → Buy | $5 |
| 2025-10-21 | init | Oppenheimer | — → Outperform | $5 |
| 2025-10-17 | init | Leerink Partners | — → Outperform | $2 |
| 2025-06-25 | main | Chardan Capital | Buy → Buy | $5 |
| 2025-05-06 | main | Chardan Capital | Buy → Buy | $5 |
| 2025-05-05 | main | Chardan Capital | Buy → Buy | $5 |
| 2024-12-17 | init | LUCID CAPITAL MARKETS | — → Buy | $6 |
| 2024-07-22 | init | Brookline Capital | — → Buy | $4 |
| 2024-06-03 | main | Chardan Capital | Buy → Buy | $5 |
| 2024-05-28 | init | Chardan Capital | — → Buy | $5 |
- IBIO Stock Price, Quote & Chart | IBIO INC (NASDAQ:IBIO) - ChartMill Fri, 17 Apr 2026 07
- iBio (IBIO) clarifies warrant expirations and advances IBIO-600 Phase 1 trial - Stock Titan Fri, 17 Apr 2026 21
- iBio Insiders Placed Bullish Bets Worth US$655.0k - Yahoo Finance Sat, 20 Dec 2025 08
- iBio Inc. (IBIO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade Fri, 10 Apr 2026 23
- Leerink reiterates Outperform on iBio stock amid competitor data - Investing.com hu, 26 Mar 2026 07
- IBIO (IBIO) price target increased by 18.73% to 5.47 - MSN Mon, 20 Apr 2026 03
- IBIO Stock Chart | IBIO INC (NASDAQ:IBIO) - ChartMill Fri, 17 Apr 2026 07
- IBIO Should I Buy - Intellectia AI ue, 31 Mar 2026 21
- iBio (NASDAQ:IBIO) CFO Felipe Duran Acquires 24,835 Shares - MarketBeat Mon, 23 Mar 2026 07
- Insider Purchase: Chief Financial Officer of $IBIO Buys 24,835 Shares - Quiver Quantitative Mon, 23 Mar 2026 07
- iBio moves muscle-preserving obesity drug into first human trial - Stock Titan Wed, 08 Apr 2026 07
- iBio, Inc. (IBIO) Reports Q1 Loss - Yahoo Finance Wed, 12 Nov 2025 08
- Jones Trading reiterates iBio stock rating on obesity drug data - Investing.com Mon, 09 Mar 2026 07
- IBIO stock is soaring today after iBio's muscle-preserving drug receives approval for human trial in Australia - MSN hu, 09 Apr 2026 04
- iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance Mon, 02 Feb 2026 08
Insider Transactions
Financials
| Line Item | Trend | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.40
+77.78%
|
0.23
|
0.00
-100.00%
|
1.88
|
| Operating Revenue |
|
0.40
+77.78%
|
0.23
|
0.00
-100.00%
|
1.88
|
| Cost Of Revenue |
|
—
|
—
|
—
|
0.22
|
| Reconciled Cost Of Revenue |
|
—
|
—
|
—
|
0.22
|
| Gross Profit |
|
—
|
—
|
—
|
2.17
|
| Operating Expense |
|
19.00
+12.71%
|
16.86
-42.55%
|
29.34
-7.09%
|
31.58
|
| Research And Development |
|
8.31
+60.31%
|
5.18
-49.79%
|
10.33
+5.09%
|
9.83
|
| Selling General And Administration |
|
10.69
-8.43%
|
11.67
-38.61%
|
19.02
-12.59%
|
21.75
|
| General And Administrative Expense |
|
10.69
-8.43%
|
11.67
-38.61%
|
19.02
-12.59%
|
21.75
|
| Other Gand A |
|
10.69
-8.43%
|
11.67
-38.61%
|
19.02
-12.59%
|
21.75
|
| Total Expenses |
|
19.00
+12.71%
|
16.86
-42.55%
|
29.34
-7.09%
|
31.58
|
| Operating Income |
|
-18.60
-11.83%
|
-16.63
+43.31%
|
-29.34
+1.19%
|
-29.70
|
| Total Operating Income As Reported |
|
-18.60
-11.83%
|
-16.63
+43.31%
|
-29.34
+1.19%
|
-29.70
|
| EBITDA |
|
-17.04
-21.52%
|
-14.02
+49.65%
|
-27.85
-8.27%
|
-25.72
|
| Normalized EBITDA |
|
-17.04
-13.43%
|
-15.02
+45.87%
|
-27.75
-7.88%
|
-25.72
|
| Reconciled Depreciation |
|
1.13
-9.92%
|
1.25
-9.42%
|
1.38
-63.60%
|
3.79
|
| EBIT |
|
-18.16
-18.95%
|
-15.27
+47.75%
|
-29.23
+0.97%
|
-29.51
|
| Total Unusual Items |
|
0.00
-100.00%
|
1.00
+1120.41%
|
-0.10
-116.14%
|
0.61
|
| Total Unusual Items Excluding Goodwill |
|
0.00
-100.00%
|
1.00
+1120.41%
|
-0.10
-116.14%
|
0.61
|
| Special Income Charges |
|
0.00
-100.00%
|
1.00
|
0.00
-100.00%
|
0.61
|
| Other Special Charges |
|
—
|
—
|
—
|
-0.61
|
| Net Income |
|
-18.38
+26.22%
|
-24.91
+61.69%
|
-65.01
-29.01%
|
-50.39
|
| Pretax Income |
|
-18.38
-19.00%
|
-15.44
+47.31%
|
-29.31
+0.68%
|
-29.51
|
| Net Non Operating Interest Income Expense |
|
0.23
+17.80%
|
0.19
+46.92%
|
0.13
-26.55%
|
0.18
|
| Interest Expense Non Operating |
|
0.21
+23.26%
|
0.17
+107.23%
|
0.08
|
0.00
|
| Net Interest Income |
|
0.23
+17.80%
|
0.19
+46.92%
|
0.13
-26.55%
|
0.18
|
| Interest Expense |
|
0.21
+23.26%
|
0.17
+107.23%
|
0.08
|
0.00
|
| Interest Income Non Operating |
|
0.44
+20.39%
|
0.36
+70.42%
|
0.21
+20.34%
|
0.18
|
| Interest Income |
|
0.44
+20.39%
|
0.36
+70.42%
|
0.21
+20.34%
|
0.18
|
| Other Income Expense |
|
—
|
1.00
+1120.41%
|
-0.10
-1500.00%
|
0.01
|
| Other Non Operating Income Expenses |
|
—
|
—
|
—
|
0.01
|
| Gain On Sale Of Security |
|
—
|
—
|
-0.10
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-18.38
+26.22%
|
-24.91
+61.69%
|
-65.01
-29.01%
|
-50.39
|
| Net Income From Continuing Operation Net Minority Interest |
|
-18.38
-19.00%
|
-15.44
+47.31%
|
-29.31
+0.68%
|
-29.51
|
| Net Income From Continuing And Discontinued Operation |
|
-18.38
+26.22%
|
-24.91
+61.69%
|
-65.01
-29.24%
|
-50.30
|
| Net Income Continuous Operations |
|
-18.38
-19.00%
|
-15.44
+47.31%
|
-29.31
+0.68%
|
-29.51
|
| Net Income Discontinuous Operations |
|
0.00
+100.00%
|
-9.46
+73.49%
|
-35.70
-71.70%
|
-20.79
|
| Minority Interests |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Normalized Income |
|
-18.38
-11.76%
|
-16.44
+43.71%
|
-29.21
+1.01%
|
-29.51
|
| Net Income Common Stockholders |
|
-18.38
+26.22%
|
-24.91
+61.69%
|
-65.01
-29.01%
|
-50.39
|
| Diluted EPS |
|
-1.75
+73.08%
|
-6.50
+93.88%
|
-106.19
+8.14%
|
-115.60
|
| Basic EPS |
|
-1.75
+73.08%
|
-6.50
+93.88%
|
-106.19
+8.14%
|
-115.60
|
| Basic Average Shares |
|
10.50
+174.05%
|
3.83
+525.98%
|
0.61
+40.35%
|
0.44
|
| Diluted Average Shares |
|
10.50
+174.05%
|
3.83
+525.98%
|
0.61
+40.35%
|
0.44
|
| Diluted NI Availto Com Stockholders |
|
-18.38
+26.22%
|
-24.91
+61.69%
|
-65.01
-29.01%
|
-50.39
|
| Gain On Sale Of PPE |
|
0.00
-100.00%
|
1.00
|
0.00
|
—
|
| Net Income From Tax Loss Carryforward |
|
—
|
—
|
0.00
+100.00%
|
-0.09
|
| Preferred Stock Dividends |
|
—
|
—
|
—
|
0.09
|
| Line Item | Trend | 2024-06-30 |
|---|---|---|
| Total Assets |
|
28.73
|
| Current Assets |
|
15.67
|
| Cash Cash Equivalents And Short Term Investments |
|
14.21
|
| Cash And Cash Equivalents |
|
14.21
|
| Other Short Term Investments |
|
—
|
| Receivables |
|
0.71
|
| Accounts Receivable |
|
—
|
| Other Receivables |
|
—
|
| Inventory |
|
—
|
| Raw Materials |
|
—
|
| Work In Process |
|
—
|
| Prepaid Assets |
|
—
|
| Restricted Cash |
|
0.00
|
| Assets Held For Sale Current |
|
0.00
|
| Other Current Assets |
|
0.75
|
| Total Non Current Assets |
|
13.06
|
| Net PPE |
|
6.37
|
| Gross PPE |
|
7.86
|
| Accumulated Depreciation |
|
-1.49
|
| Properties |
|
0.00
|
| Buildings And Improvements |
|
0.69
|
| Machinery Furniture Equipment |
|
3.95
|
| Construction In Progress |
|
—
|
| Other Properties |
|
3.21
|
| Goodwill And Other Intangible Assets |
|
5.37
|
| Other Intangible Assets |
|
5.37
|
| Non Current Accounts Receivable |
|
—
|
| Non Current Prepaid Assets |
|
0.03
|
| Other Non Current Assets |
|
0.21
|
| Total Liabilities Net Minority Interest |
|
7.41
|
| Current Liabilities |
|
3.84
|
| Payables And Accrued Expenses |
|
1.12
|
| Payables |
|
0.66
|
| Accounts Payable |
|
0.36
|
| Other Payable |
|
0.30
|
| Current Accrued Expenses |
|
0.46
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1.57
|
| Total Tax Payable |
|
0.00
|
| Current Debt And Capital Lease Obligation |
|
0.95
|
| Current Debt |
|
0.22
|
| Other Current Borrowings |
|
0.22
|
| Current Capital Lease Obligation |
|
0.73
|
| Current Deferred Liabilities |
|
0.20
|
| Current Deferred Revenue |
|
0.20
|
| Other Current Liabilities |
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
3.57
|
| Liabilities Heldfor Sale Non Current |
|
—
|
| Long Term Debt And Capital Lease Obligation |
|
3.51
|
| Long Term Debt |
|
0.77
|
| Long Term Capital Lease Obligation |
|
2.74
|
| Tradeand Other Payables Non Current |
|
0.06
|
| Stockholders Equity |
|
21.32
|
| Common Stock Equity |
|
21.32
|
| Capital Stock |
|
0.01
|
| Common Stock |
|
0.01
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
8.62
|
| Ordinary Shares Number |
|
8.62
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
335.16
|
| Retained Earnings |
|
-313.85
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
| Minority Interest |
|
—
|
| Other Equity Adjustments |
|
—
|
| Total Equity Gross Minority Interest |
|
21.32
|
| Total Capitalization |
|
22.09
|
| Working Capital |
|
11.83
|
| Invested Capital |
|
22.31
|
| Total Debt |
|
4.46
|
| Net Debt |
|
—
|
| Capital Lease Obligations |
|
3.48
|
| Net Tangible Assets |
|
15.96
|
| Tangible Book Value |
|
15.96
|
| Current Notes Payable |
|
0.00
|
| Interest Payable |
|
0.00
|
| Non Current Accrued Expenses |
|
—
|
| Non Current Note Receivables |
|
1.08
|
| Notes Receivable |
|
0.71
|
| Line Item | Trend | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-15.30
+17.52%
|
-18.55
+39.04%
|
-30.44
+18.79%
|
-37.48
|
| Cash Flow From Continuing Operating Activities |
|
-15.30
+17.52%
|
-18.55
+39.04%
|
-30.44
+18.79%
|
-37.48
|
| Net Income From Continuing Operations |
|
-18.38
+26.22%
|
-24.91
+61.69%
|
-65.01
-29.23%
|
-50.30
|
| Depreciation Amortization Depletion |
|
1.13
-9.92%
|
1.25
-9.42%
|
1.38
-63.60%
|
3.79
|
| Depreciation |
|
1.11
-10.08%
|
1.23
-1.91%
|
1.25
-63.01%
|
3.39
|
| Amortization Cash Flow |
|
0.02
+0.00%
|
0.02
-84.13%
|
0.13
-68.58%
|
0.40
|
| Depreciation And Amortization |
|
1.13
-9.92%
|
1.25
-9.42%
|
1.38
-63.60%
|
3.79
|
| Amortization Of Intangibles |
|
0.02
+0.00%
|
0.02
-84.13%
|
0.13
-68.58%
|
0.40
|
| Other Non Cash Items |
|
-0.06
-293.75%
|
0.03
-80.84%
|
0.17
+421.15%
|
-0.05
|
| Stock Based Compensation |
|
1.53
-24.93%
|
2.04
-53.59%
|
4.39
+0.32%
|
4.38
|
| Provisionand Write Offof Assets |
|
—
|
0.00
-100.00%
|
4.92
|
0.00
|
| Asset Impairment Charge |
|
0.00
-100.00%
|
3.10
-83.21%
|
18.46
+949.15%
|
1.76
|
| Operating Gains Losses |
|
—
|
3.10
+556.03%
|
-0.68
-12.03%
|
-0.61
|
| Gain Loss On Investment Securities |
|
—
|
—
|
0.10
|
—
|
| Gain Loss On Sale Of PPE |
|
0.00
-100.00%
|
3.91
+605.69%
|
-0.77
|
0.00
|
| Change In Working Capital |
|
0.48
+115.12%
|
-3.17
-153.98%
|
5.87
+80.97%
|
3.24
|
| Change In Receivables |
|
—
|
0.00
-100.00%
|
6.10
+44.76%
|
4.21
|
| Changes In Account Receivables |
|
—
|
0.00
-100.00%
|
1.00
+212.87%
|
-0.89
|
| Change In Inventory |
|
—
|
0.00
+100.00%
|
-1.01
+73.79%
|
-3.87
|
| Change In Prepaid Assets |
|
-0.41
-271.43%
|
0.24
-74.63%
|
0.94
+311.40%
|
0.23
|
| Change In Payables And Accrued Expense |
|
1.07
+133.35%
|
-3.22
-6944.68%
|
0.05
-98.25%
|
2.68
|
| Change In Accrued Expense |
|
-0.76
+56.08%
|
-1.73
-356.85%
|
0.67
-53.43%
|
1.44
|
| Change In Payable |
|
1.83
+222.80%
|
-1.49
-138.56%
|
-0.62
-150.44%
|
1.24
|
| Change In Account Payable |
|
1.83
+222.80%
|
-1.49
-138.56%
|
-0.62
-150.44%
|
1.24
|
| Change In Other Working Capital |
|
0.25
+25.00%
|
0.20
+300.00%
|
-0.10
-1528.57%
|
0.01
|
| Change In Other Current Liabilities |
|
-0.44
-12.08%
|
-0.39
-285.15%
|
-0.10
-573.33%
|
-0.01
|
| Investing Cash Flow |
|
0.74
-18.10%
|
0.91
-87.07%
|
7.01
+236.71%
|
-5.13
|
| Cash Flow From Continuing Investing Activities |
|
0.74
-18.10%
|
0.91
-87.07%
|
7.01
+236.71%
|
-5.13
|
| Net PPE Purchase And Sale |
|
-0.02
+82.98%
|
-0.09
+97.00%
|
-3.14
+57.19%
|
-7.33
|
| Purchase Of PPE |
|
-0.02
+92.38%
|
-0.21
+96.34%
|
-5.74
+21.72%
|
-7.33
|
| Sale Of PPE |
|
0.00
-100.00%
|
0.12
-95.54%
|
2.60
|
0.00
|
| Capital Expenditure |
|
-0.02
+92.38%
|
-0.21
+96.34%
|
-5.74
+50.66%
|
-11.63
|
| Net Investment Purchase And Sale |
|
—
|
0.00
-100.00%
|
10.84
+66.68%
|
6.50
|
| Purchase Of Investment |
|
—
|
—
|
0.00
+100.00%
|
-7.12
|
| Sale Of Investment |
|
—
|
0.00
-100.00%
|
10.84
-20.41%
|
13.62
|
| Net Business Purchase And Sale |
|
—
|
0.00
+100.00%
|
-0.69
|
0.00
|
| Purchase Of Business |
|
—
|
0.00
+100.00%
|
-0.69
|
0.00
|
| Net Intangibles Purchase And Sale |
|
0.00
-100.00%
|
1.00
|
0.00
+100.00%
|
-4.30
|
| Purchase Of Intangibles |
|
—
|
—
|
0.00
+100.00%
|
-4.30
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
—
|
| Financing Cash Flow |
|
8.93
-63.55%
|
24.49
+964.49%
|
2.30
+137.57%
|
-6.12
|
| Cash Flow From Continuing Financing Activities |
|
8.93
-63.55%
|
24.49
+964.49%
|
2.30
+137.57%
|
-6.12
|
| Net Issuance Payments Of Debt |
|
-0.69
+38.93%
|
-1.14
+87.53%
|
-9.12
-56.52%
|
-5.83
|
| Issuance Of Debt |
|
0.00
-100.00%
|
0.90
+79.00%
|
0.50
|
0.00
|
| Repayment Of Debt |
|
-0.69
+65.81%
|
-2.03
+78.88%
|
-9.62
-65.09%
|
-5.83
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
0.90
+79.00%
|
0.50
|
0.00
|
| Long Term Debt Payments |
|
-0.69
-33.65%
|
-0.52
-69.38%
|
-0.31
+94.73%
|
-5.83
|
| Net Long Term Debt Issuance |
|
-0.69
-285.33%
|
0.38
+94.30%
|
0.19
+103.31%
|
-5.83
|
| Short Term Debt Payments |
|
0.00
+100.00%
|
-1.51
+83.76%
|
-9.32
|
0.00
|
| Net Short Term Debt Issuance |
|
0.00
+100.00%
|
-1.51
+83.76%
|
-9.32
|
0.00
|
| Net Common Stock Issuance |
|
3.54
-86.12%
|
25.52
+122.89%
|
11.45
|
0.00
|
| Common Stock Payments |
|
0.00
+100.00%
|
-0.01
+82.05%
|
-0.04
|
0.00
|
| Repurchase Of Capital Stock |
|
0.00
+100.00%
|
-0.01
+82.05%
|
-0.04
|
0.00
|
| Proceeds From Stock Option Exercised |
|
6.38
|
0.00
|
0.00
-100.00%
|
0.08
|
| Net Other Financing Charges |
|
-0.29
-353.45%
|
0.12
+627.27%
|
-0.02
+94.09%
|
-0.37
|
| Changes In Cash |
|
-5.63
-182.28%
|
6.85
+132.41%
|
-21.13
+56.65%
|
-48.73
|
| Effect Of Exchange Rate Changes |
|
—
|
0.00
-100.00%
|
0.03
|
0.00
|
| Beginning Cash Position |
|
14.43
+90.33%
|
7.58
-73.57%
|
28.67
-62.96%
|
77.40
|
| End Cash Position |
|
8.79
-39.05%
|
14.43
+90.33%
|
7.58
-73.57%
|
28.67
|
| Free Cash Flow |
|
-15.32
+18.35%
|
-18.76
+48.13%
|
-36.17
+26.34%
|
-49.11
|
| Interest Paid Supplemental Data |
|
0.21
-71.70%
|
0.75
+9.02%
|
0.69
-34.26%
|
1.04
|
| Amortization Of Securities |
|
—
|
0.00
-100.00%
|
0.07
-78.53%
|
0.31
|
| Common Stock Issuance |
|
3.54
-86.13%
|
25.52
+122.19%
|
11.49
|
0.00
|
| Interest Received CFI |
|
0.76
|
0.00
|
—
|
—
|
| Issuance Of Capital Stock |
|
3.54
-86.13%
|
25.52
+122.19%
|
11.49
|
0.00
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Sale Of Intangibles |
|
0.00
-100.00%
|
1.00
|
0.00
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-08 View
- 42026-03-27 View
- 42026-03-23 View
- 42026-03-23 View
- 8-K2026-03-09 View
- 8-K2026-02-27 View
- 10-Q2026-02-10 View
- 8-K2026-02-10 View
- 42026-01-30 View
- 42026-01-30 View
- 42026-01-30 View
- 8-K2026-01-12 View
- 42025-11-24 View
- 42025-11-24 View
- 42025-11-24 View
- 42025-11-24 View
- 42025-11-24 View
- 42025-11-24 View
- 8-K2025-11-21 View
- 8-K2025-11-17 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|